AP3310A - Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia - Google Patents
Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophreniaInfo
- Publication number
- AP3310A AP3310A AP2013007338A AP2013007338A AP3310A AP 3310 A AP3310 A AP 3310A AP 2013007338 A AP2013007338 A AP 2013007338A AP 2013007338 A AP2013007338 A AP 2013007338A AP 3310 A AP3310 A AP 3310A
- Authority
- AP
- ARIPO
- Prior art keywords
- piperazino
- deuterated
- schizophrenia
- treatment
- indanes
- Prior art date
Links
- QPABODDHXQJCDN-UHFFFAOYSA-N 1-(3-phenyl-2,3-dihydro-1h-inden-1-yl)piperazine Chemical class C12=CC=CC=C2C(C=2C=CC=CC=2)CC1N1CCNCC1 QPABODDHXQJCDN-UHFFFAOYSA-N 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498651P | 2011-06-20 | 2011-06-20 | |
US201161537103P | 2011-09-21 | 2011-09-21 | |
PCT/IB2012/001386 WO2012176066A1 (en) | 2011-06-20 | 2012-06-19 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2013007338A0 AP2013007338A0 (en) | 2013-12-31 |
AP3310A true AP3310A (en) | 2015-06-30 |
Family
ID=46682855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2013007338A AP3310A (en) | 2011-06-20 | 2012-06-19 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |
Country Status (40)
Country | Link |
---|---|
US (8) | US8575174B2 (ro) |
EP (4) | EP3135656B1 (ro) |
JP (1) | JP5668177B2 (ro) |
KR (2) | KR101939546B1 (ro) |
CN (1) | CN103649019B (ro) |
AP (1) | AP3310A (ro) |
AR (1) | AR086987A1 (ro) |
AU (1) | AU2012273657B2 (ro) |
BR (1) | BR112013031702B1 (ro) |
CA (1) | CA2837820C (ro) |
CL (1) | CL2013003646A1 (ro) |
CO (1) | CO6821965A2 (ro) |
CR (1) | CR20130654A (ro) |
CY (2) | CY1118158T1 (ro) |
DK (2) | DK3135656T3 (ro) |
DO (1) | DOP2013000305A (ro) |
EA (1) | EA024651B1 (ro) |
EC (1) | ECSP14013155A (ro) |
ES (3) | ES2719145T3 (ro) |
GE (1) | GEP201706655B (ro) |
GT (1) | GT201300304A (ro) |
HK (1) | HK1197228A1 (ro) |
HR (2) | HRP20161348T1 (ro) |
HU (2) | HUE030883T2 (ro) |
IL (1) | IL229640B (ro) |
JO (1) | JO3128B1 (ro) |
LT (2) | LT3135656T (ro) |
MA (1) | MA35268B1 (ro) |
MD (1) | MD4538C1 (ro) |
ME (2) | ME03375B (ro) |
MX (1) | MX339552B (ro) |
MY (1) | MY196998A (ro) |
PE (2) | PE20150928A1 (ro) |
PL (2) | PL2720989T3 (ro) |
PT (2) | PT2720989T (ro) |
RS (2) | RS58546B1 (ro) |
SI (2) | SI2720989T1 (ro) |
SM (1) | SMT201600383B (ro) |
TW (3) | TWI627956B (ro) |
WO (1) | WO2012176066A1 (ro) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2719145T3 (es) | 2011-06-20 | 2019-07-08 | H Lundbeck As | 1-Piperazino-3-fenil-indanos deuterados para el tratamiento de la esquizofrenia |
AR094054A1 (es) * | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
EP3679018B1 (en) | 2017-09-07 | 2022-03-02 | Otsuka Pharmaceutical Co., Ltd. | Industrial process of mono-alkylating a piperidine nitrogen in piperidine derivatives with deuterated-alkyl |
EP3873885A1 (en) | 2018-10-29 | 2021-09-08 | H. Lundbeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
US11535600B2 (en) | 2018-12-03 | 2022-12-27 | H. Lundbeck A/S | Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine |
AU2019403391A1 (en) * | 2018-12-21 | 2021-08-05 | Terran Biosciences, Inc. | Deuterated forms and derivatives of volinanserin |
EP3939954A4 (en) | 2019-03-13 | 2023-01-04 | Otsuka Pharmaceutical Co., Ltd. | METHOD FOR INTRODUCING A DEUTERED LOWER ALKYL INTO AN AMINE FRACTION OF A COMPOUND CONTAINING A SECONDARY AMINE |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022293A1 (en) * | 1992-04-28 | 1993-11-11 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
WO2005016901A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
GB8427125D0 (en) | 1984-10-26 | 1984-12-05 | Lundbeck & Co As H | Organic compounds |
WO2010037398A1 (en) | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
DK286990D0 (da) | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | Indanderivater |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO1995026325A2 (en) | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
CN101935305B (zh) * | 2003-08-18 | 2013-04-10 | H.隆德贝克有限公司 | 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪及其盐的制备方法及所用中间体 |
JP2008530039A (ja) * | 2005-02-16 | 2008-08-07 | ハー・ルンドベック・アクチエゼルスカベット | トランス−1−((1r,3s)−6−クロロ−3−フェニルインダン−1−イル)−3,3−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩 |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
EP1910322B1 (en) | 2005-07-29 | 2012-09-05 | Concert Pharmaceuticals Inc. | Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
EP1954669B1 (en) | 2005-12-01 | 2015-07-08 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
JP4986462B2 (ja) | 2006-01-27 | 2012-07-25 | シャープ株式会社 | 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
WO2008128166A1 (en) | 2007-04-13 | 2008-10-23 | Concert Pharmaceuticals Inc. | Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds |
US7528131B2 (en) | 2007-04-19 | 2009-05-05 | Concert Pharmaceuticals Inc. | Substituted morpholinyl compounds |
MX2009013565A (es) | 2007-06-12 | 2010-06-02 | Concert Pharmaceuticals Inc | Derivados de azapeptidos. |
US20090062303A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched ziprasidone |
NZ589571A (en) | 2008-05-07 | 2012-07-27 | Lundbeck & Co As H | Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine |
EP2362865A2 (en) | 2008-10-28 | 2011-09-07 | Concert Pharmaceuticals Inc. | Deuterated 2-propylpentanoic acid compounds |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US8658236B2 (en) * | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
CN102020522A (zh) * | 2009-09-21 | 2011-04-20 | 陈松源 | 氘代药物的制备方法和应用 |
WO2011047315A1 (en) | 2009-10-15 | 2011-04-21 | Concert Pharmaceuticals, Inc. | Subsitituted benzimidazoles |
WO2011059080A1 (ja) * | 2009-11-16 | 2011-05-19 | 第一三共株式会社 | 同位体置換されたジアミン誘導体 |
ES2719145T3 (es) * | 2011-06-20 | 2019-07-08 | H Lundbeck As | 1-Piperazino-3-fenil-indanos deuterados para el tratamiento de la esquizofrenia |
-
2012
- 2012-06-19 ES ES16179882T patent/ES2719145T3/es active Active
- 2012-06-19 ME MEP-2019-93A patent/ME03375B/me unknown
- 2012-06-19 EP EP16179882.2A patent/EP3135656B1/en active Active
- 2012-06-19 PE PE2015000596A patent/PE20150928A1/es active IP Right Grant
- 2012-06-19 BR BR112013031702-7A patent/BR112013031702B1/pt active IP Right Grant
- 2012-06-19 PE PE2013002857A patent/PE20141113A1/es not_active Application Discontinuation
- 2012-06-19 RS RS20190429A patent/RS58546B1/sr unknown
- 2012-06-19 KR KR1020187018343A patent/KR101939546B1/ko active IP Right Grant
- 2012-06-19 LT LTEP16179882.2T patent/LT3135656T/lt unknown
- 2012-06-19 PL PL12748046T patent/PL2720989T3/pl unknown
- 2012-06-19 CN CN201280029731.8A patent/CN103649019B/zh active Active
- 2012-06-19 GE GEAP201213350A patent/GEP201706655B/en unknown
- 2012-06-19 ES ES12748046.5T patent/ES2601213T3/es active Active
- 2012-06-19 WO PCT/IB2012/001386 patent/WO2012176066A1/en active Application Filing
- 2012-06-19 AU AU2012273657A patent/AU2012273657B2/en active Active
- 2012-06-19 EP EP12748046.5A patent/EP2720989B1/en active Active
- 2012-06-19 KR KR1020137033717A patent/KR101879474B1/ko active IP Right Grant
- 2012-06-19 PT PT127480465T patent/PT2720989T/pt unknown
- 2012-06-19 ME MEP-2016-226A patent/ME02513B/me unknown
- 2012-06-19 MY MYPI2021002383A patent/MY196998A/en unknown
- 2012-06-19 MX MX2013014849A patent/MX339552B/es active IP Right Grant
- 2012-06-19 RS RS20160916A patent/RS55304B1/sr unknown
- 2012-06-19 DK DK16179882.2T patent/DK3135656T3/en active
- 2012-06-19 SI SI201230744A patent/SI2720989T1/sl unknown
- 2012-06-19 JP JP2014516459A patent/JP5668177B2/ja active Active
- 2012-06-19 AP AP2013007338A patent/AP3310A/xx active
- 2012-06-19 HU HUE12748046A patent/HUE030883T2/en unknown
- 2012-06-19 JO JOP/2012/0161A patent/JO3128B1/ar active
- 2012-06-19 PL PL16179882T patent/PL3135656T3/pl unknown
- 2012-06-19 CA CA2837820A patent/CA2837820C/en active Active
- 2012-06-19 EP EP19151618.6A patent/EP3508468B1/en active Active
- 2012-06-19 HU HUE16179882A patent/HUE044043T2/hu unknown
- 2012-06-19 EA EA201490045A patent/EA024651B1/ru not_active IP Right Cessation
- 2012-06-19 US US13/527,364 patent/US8575174B2/en active Active
- 2012-06-19 ES ES19151618T patent/ES2939477T3/es active Active
- 2012-06-19 LT LTEP12748046.5T patent/LT2720989T/lt unknown
- 2012-06-19 PT PT16179882T patent/PT3135656T/pt unknown
- 2012-06-19 SI SI201231582T patent/SI3135656T1/sl unknown
- 2012-06-19 EP EP23150855.7A patent/EP4215512A1/en active Pending
- 2012-06-19 AR ARP120102179 patent/AR086987A1/es active IP Right Grant
- 2012-06-19 MD MDA20140004A patent/MD4538C1/ro active IP Right Grant
- 2012-06-19 DK DK12748046.5T patent/DK2720989T3/en active
- 2012-06-20 TW TW101122028A patent/TWI627956B/zh active
- 2012-06-20 TW TW106107563A patent/TWI614234B/zh active
- 2012-06-20 TW TW107113541A patent/TWI659741B/zh active
-
2013
- 2013-06-24 US US13/924,849 patent/US9012453B2/en active Active
- 2013-11-26 IL IL229640A patent/IL229640B/en active IP Right Grant
- 2013-12-09 GT GT201300304A patent/GT201300304A/es unknown
- 2013-12-13 CR CR20130654A patent/CR20130654A/es unknown
- 2013-12-16 DO DO2013000305A patent/DOP2013000305A/es unknown
- 2013-12-19 CO CO13296680A patent/CO6821965A2/es active IP Right Grant
- 2013-12-19 CL CL2013003646A patent/CL2013003646A1/es unknown
-
2014
- 2014-01-16 MA MA36688A patent/MA35268B1/fr unknown
- 2014-01-17 EC ECSP14013155 patent/ECSP14013155A/es unknown
- 2014-10-22 HK HK14110519A patent/HK1197228A1/zh unknown
-
2015
- 2015-03-13 US US14/656,925 patent/US9216961B2/en active Active
- 2015-11-16 US US14/941,800 patent/US9617231B2/en active Active
-
2016
- 2016-10-17 HR HRP20161348TT patent/HRP20161348T1/hr unknown
- 2016-10-26 CY CY20161101089T patent/CY1118158T1/el unknown
- 2016-10-26 SM SM201600383T patent/SMT201600383B/it unknown
-
2017
- 2017-02-17 US US15/435,826 patent/US10118907B2/en active Active
-
2018
- 2018-09-28 US US16/146,625 patent/US10501427B2/en active Active
-
2019
- 2019-03-27 HR HRP20190593TT patent/HRP20190593T1/hr unknown
- 2019-04-02 CY CY20191100368T patent/CY1121514T1/el unknown
- 2019-11-04 US US16/672,870 patent/US11059798B2/en active Active
-
2021
- 2021-06-07 US US17/340,201 patent/US20220119362A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022293A1 (en) * | 1992-04-28 | 1993-11-11 | H. Lundbeck A/S | 1-piperazino-1,2-dihydroindene derivatives |
WO2005016901A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
HRP20190593T1 (hr) | Deuterirani 1-piperazino-3-fenil indani za liječenje shizofrenije | |
HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
EP2773754A4 (en) | Methods of Treatment | |
EP2717855A4 (en) | PROCESSING METHODS | |
GB201110095D0 (en) | Method of treatment | |
GB201106960D0 (en) | Treatment of waste | |
HK1199261A1 (en) | Methods for treatment of diseases | |
EP2709665A4 (en) | TREATMENT OF PSORIASIS | |
ZA201309613B (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
EP2791324A4 (en) | PROCESSING METHOD | |
HK1199818A1 (en) | Treatment of seborrhoea | |
GB201118065D0 (en) | Treatment of movement disorders | |
GB201110602D0 (en) | Methods of treatment | |
GB201109737D0 (en) | Methods of treatment | |
EP2696872A4 (en) | TREATMENT OF GLAUCOMA | |
GB201121044D0 (en) | Treatment of solutions | |
GB201118269D0 (en) | Treatment of cardiovascular disease | |
GB201111530D0 (en) | Method of treatment | |
GB201109509D0 (en) | Method of treatment | |
GB201109266D0 (en) | Method of treatment | |
GB201107988D0 (en) | Treatment of cardiovascular disease | |
GB201103044D0 (en) | Method of treatment |